Neurocrine Biosciences Inc (NBIX)
Inventory turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Cost of revenue | US$ in thousands | 1,044,800 | 930,800 | 776,400 | 583,300 | 433,300 |
Inventory | US$ in thousands | 57,400 | 38,300 | 35,100 | 30,500 | 28,000 |
Inventory turnover | 18.20 | 24.30 | 22.12 | 19.12 | 15.48 |
December 31, 2024 calculation
Inventory turnover = Cost of revenue ÷ Inventory
= $1,044,800K ÷ $57,400K
= 18.20
Neurocrine Biosciences Inc's inventory turnover has shown a positive trend over the years, increasing from 15.48 in 2020 to 19.12 in 2021, further rising to 22.12 in 2022, and reaching 24.30 in 2023. This indicates that the company has been efficient in managing its inventory levels and converting them into sales. However, there was a slight decrease in inventory turnover to 18.20 in 2024. Overall, Neurocrine Biosciences Inc's inventory turnover ratios suggest effective inventory management practices and a healthy demand for its products during the period under review.
Peer comparison
Dec 31, 2024
Company name
Symbol
Inventory turnover
Neurocrine Biosciences Inc
NBIX
18.20
ADMA Biologics Inc
ADMA
0.98
Amgen Inc
AMGN
1.90
Bio-Techne Corp
TECH
5.45
Biogen Inc
BIIB
2.09
Gilead Sciences Inc
GILD
8.77
Halozyme Therapeutics Inc
HALO
3.30
Krystal Biotech Inc
KRYS
4.29
Moderna Inc
MRNA
37.46
Repligen Corporation
RGEN
3.16
Vericel Corp Ord
VCEL
4.73